Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial.

MLA

Pai, Menaka, et al. “Low-Molecular-Weight Heparin Venous Thromboprophylaxis in Critically Ill Patients with Renal Dysfunction: A Subgroup Analysis of the PROTECT Trial.” PloS One, vol. 13, no. 6, June 2018, p. e0198285. EBSCOhost, https://doi.org/10.1371/journal.pone.0198285.

APA

Pai, M., Adhikari, N. K. J., Ostermann, M., Heels-Ansdell, D., Douketis, J. D., Skrobik, Y., Qushmaq, I., Meade, M., Guyatt, G., Geerts, W., Walsh, M. W., Crowther, M. A., Friedrich, J. O., Burry, L., Bellomo, R., Brandão da Silva, N., Costa Filho, R., Cox, M. J., Alves Silva, S., & Cook, D. J. (2018). Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial. PloS One, 13(6), e0198285. https://doi.org/10.1371/journal.pone.0198285

Chicago

Pai, Menaka, Neill K J Adhikari, Marlies Ostermann, Diane Heels-Ansdell, James D Douketis, Yoanna Skrobik, Ismael Qushmaq, et al. 2018. “Low-Molecular-Weight Heparin Venous Thromboprophylaxis in Critically Ill Patients with Renal Dysfunction: A Subgroup Analysis of the PROTECT Trial.” PloS One 13 (6): e0198285. doi:10.1371/journal.pone.0198285.